The Glycemia Risk Index (GRI) and Continuous Glucose Monitoring Index (COGI) are newly defined composite metric parameters derived from continuous glucose monitoring (CGM) data. GRI is divided into five separate risk zones (from lowest to highest: A-E). In this study, the effect of the advanced hybrid closed loop (AHCL) system on GRI and COGI in children with type 1 diabetes was evaluated. Forty-five children who had started using the AHCL and whose baseline and sixth-month CGM data were available were analyzed in terms of achievement of CGM consensus goals and changes in GRI scores and zones. The paired -test was used for the analyses. The mean age and duration of diabetes of the participants were 10.95 ± 3.41 and 3.85 ± 2.67 years, respectively. The mean GRI score significantly decreased from 35.66 ± 17.46 at baseline to 22.83 ± 9.08 at 6 months ( < 0.001). Although the proportion of those in the A zone was 20% at baseline, it increased to 42% at 6 months. AHCL also improved COGI from 72.59 ± 12.44 to 82.90 ± 7.72 ( < 0.001). Time in range (TIR) increased significantly from 70.54% to 80.51% ( < 0.001) at 6 months. AHCL provides not only an improvement in TIR but also a significant improvement in both GRI and COGI at 6 months. The incorporation of GRI and COGI alongside TIR may enhance the assessment of the glycemic profile by providing a more comprehensive and in-depth analysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/dia.2023.0112 | DOI Listing |
Iran J Basic Med Sci
January 2025
School of Physical Education, Department of Sports Health, Central China Normal University, Wuhan, 430079, China.
Objectives: This study aimed to evaluate the effects of pre-conditioning exercise on body lipid metabolism, leptin secretion, and the downstream pathways at the early stage of type 2 diabetes mellitus (T2DM).
Materials And Methods: The T2DM model was established using an 8-week high-sugar, high-fat diet combined. The T2DM model was established using an 8-week high-sugar, high-fat diet combined with streptozocin (STZ) injection.
Diabetol Int
January 2025
Department of Clinical Nutrition, National Hospital Organization Kyoto Medical Center, 1-1Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555 Japan.
Background: This study aimed to compare the economic value of intermittent-scanning continuous glucose monitoring (isCGM) with self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D).
Methods: Participants were placed on either an isCGM or SMBG arm for 84 days, in a randomized, crossover setup with a 28-day washout period. Clinically relevant hypoglycemia (<54 mg/dL) and severe hypoglycemia (SH) risks were calculated by analyzing the data from isCGM.
Diabetol Int
January 2025
Department of Metabolic Medicine, Kumamoto City Hospital, 4-1-60 Higashimachi, Higashi-ku, Kumamoto, 862-8505 Japan.
A 58-year-old woman with a body mass index of 26.4 kg/m was referred because of high glycated hemoglobin (HbA1c) at a medical checkup. Her anti-glutamic acid decarboxylase antibody (GADA) titer was positive (16.
View Article and Find Full Text PDFAm J Med Genet C Semin Med Genet
January 2025
Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
Patients with Turner Syndrome (TS) and those exposed to high concentrations of glucocorticoids have a number of characteristics in common, including an increased risk of cardiovascular disease. Pediatric TS patients underwent studies of salivary cortisol (SC) and cortisone (SCn), body composition, continuous glucose monitoring, vascular function, and ambulatory blood pressure (BP). Biochemical indicators of cardiovascular risk were also measured.
View Article and Find Full Text PDFDiabet Med
January 2025
Diabetes and Endocrine Centre, Sheffield Teaching Hospitals, Sheffield, UK.
Aims: This study assessed real-world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes.
Methods: In this single-site prospective study, adults with type 1 (T1D) or type 2 diabetes (T2D) taking two or more insulin injections per day initiated Dexcom ONE CGM use and attended follow-up data collection visits after 3 and 6 months. During the study, participants received usual diabetes care.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!